Related Experiment Video

Updated: Jul 8, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

Cost and cost-effectiveness of childhood vaccination against rotavirus in France

H Melliez1, D Levybruhl, P Y Boelle

  • 1Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France. hugues.melliez@orange.fr <hugues.melliez@orange.fr>

Vaccine
|January 2, 2008
PubMed

Insights

Routine childhood rotavirus vaccination in France significantly reduces illness and deaths. However, it is not cost-effective at current prices, requiring a substantial vaccine cost reduction for broader implementation.

Area of Science:

  • Public Health
  • Epidemiology
  • Health Economics

Background:

  • Rotavirus infection is a significant cause of childhood diarrhea and hospitalization.
  • New rotavirus vaccines offer potential for disease prevention.

Purpose of the Study:

  • To evaluate the effectiveness and cost-effectiveness of routine childhood rotavirus vaccination in France.
  • To model the impact of rotavirus vaccination on disease burden and healthcare costs.

Main Methods:

  • A Markov decision tree model was used to compare vaccination with no vaccination.
  • A hypothetical cohort of 750,000 children was followed to age 3.
  • Disease burden and vaccine efficacy data were sourced from French databases and medical literature.

Main Results:

  • Routine vaccination could annually prevent 89,000 diarrhea cases, 10,500 hospitalizations, and 8 deaths.
  • At €150/course and 75% coverage, the program costs €95 million, resulting in a net loss of €68 million.
  • The cost per year of life saved was €298,000, and per QALY saved was €138,000.

Conclusions:

  • Childhood rotavirus vaccination reduces morbidity from rotavirus infections in France.
  • Current vaccine prices make the program not cost-effective.
  • A significant decrease in vaccine price is necessary for cost-effectiveness.
Abstract

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...